Acrivon Therapeutics Inc (ACRV) Stock Price, Quote & News

Company Profile

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 207 8979

Website: acrivon.com

Address:

480 Arsenal Way, Suite 100, Watertown, United States

Jstidd Nov. 14 at 6:44 PM

$ACRV great ER, up 11% today...and STILL only 857 followers? is this thing on ?!?! 🎤 this is my largest position by far.

1 · Reply

History101 Nov. 14 at 4:42 PM

$ACRV up 100% in 6mos...

0 · Reply

History101 Nov. 14 at 4:41 PM

$ACRV an oversubscribed private placement was done in April of 2024 at $8.50/share, raised $130MM. ACRV market cap is now $71MM. Do the math. ACRV is now my largest position. GLTALs!!

0 · Reply

Trinity031983 Nov. 14 at 1:38 PM

$ACRV https://tipranks.onelink.me/WJho/5ym5slw0

0 · Reply

Trinity031983 Nov. 14 at 1:12 PM

$ACRV https://tipranks.onelink.me/WJho/35lnqr16

0 · Reply

Trinity031983 Nov. 14 at 1:08 PM

$ACRV https://tipranks.onelink.me/WJho/gmlsldqi

0 · Reply

trading_momentum_x Nov. 14 at 12:22 PM

Stocks Watchlist for today : $ACRV - bull channel continuation $KITT - bottom play $WORX - potential accumulation candle last week price should see over .40 if true $SGBX - squeeze candidate ELWS - cup and handle on watch for breakout $INTS - mini flag on 4hr

0 · Reply

d_risk Nov. 13 at 9:38 PM

$ACRV - Acrivon Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors ACRV’s updated risk factors highlight rising net losses, higher expenses from clinical and commercial activities, a cash runway into Q2 2027, and new concerns about potential disruptions at key government agencies impacting operations. #Biotechnology #CashRunway #GovernmentRegulation #FinancialRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/ACRV/10-Q/2025-11-13

1 · Reply

Monty3030 Nov. 13 at 9:21 PM

$ACRV Earnings Report.. Looking good!! https://www.stocktitan.net/news/ACRV/acrivon-therapeutics-reports-third-quarter-2025-financial-results-hqypngwadrf8.html

0 · Reply

MH2024 Nov. 13 at 3:08 PM

$ACRV I think we will see some near term ups and downs and the real movement after the new year.

0 · Reply

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 22, 2025, 4:15 PM EDT - 23 days ago

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

Oct 1, 2025, 4:30 PM EDT - 6 weeks ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2025, 4:15 PM EDT - 3 months ago

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 4:10 PM EDT - 6 months ago

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Apr 25, 2025, 8:00 AM EDT - 7 months ago

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Apr 7, 2025, 4:05 PM EDT - 7 months ago

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Mar 27, 2025, 5:44 PM EDT - 8 months ago

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 19, 2025, 8:00 AM EDT - 8 months ago

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Dec 12, 2024, 3:25 PM EST - 1 year ago

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Sep 18, 2024, 10:11 AM EDT - 1 year ago

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Sep 14, 2024, 3:10 AM EDT - 1 year ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Jun 13, 2024, 2:00 PM EDT - 1 year ago

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?

May 29, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 24, 2024, 7:16 PM EDT - 1 year ago

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Apr 16, 2024, 8:01 PM EDT - 1 year ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Apr 3, 2024, 3:07 AM EDT - 1 year ago

What To Buy After You Sell The Russell 2000

AVUV IJR IWM IWN MLYS NXT SKWD

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 5, 2024, 4:30 PM EST - 1 year ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Feb 27, 2024, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 12, 2024, 4:00 PM EST - 2 years ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 21, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Nov 9, 2023, 8:01 AM EST - 2 years ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 19, 2023, 4:32 PM EDT - 2 years ago

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Sep 5, 2023, 4:05 PM EDT - 2 years ago

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jun 22, 2023, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Mar 26, 2023, 9:53 AM EDT - 2 years ago

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Mar 6, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Nov 14, 2022, 10:16 PM EST - 3 years ago

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Nov 3, 2022, 7:52 AM EDT - 3 years ago

Acrivon Therapeutics sets IPO price range

Oct 19, 2022, 11:50 AM EDT - 3 years ago

Acrivon Therapeutics Begins U.S. IPO Rollout

Jstidd Nov. 14 at 6:44 PM

$ACRV great ER, up 11% today...and STILL only 857 followers? is this thing on ?!?! 🎤 this is my largest position by far.

1 · Reply

History101 Nov. 14 at 4:42 PM

$ACRV up 100% in 6mos...

0 · Reply

History101 Nov. 14 at 4:41 PM

$ACRV an oversubscribed private placement was done in April of 2024 at $8.50/share, raised $130MM. ACRV market cap is now $71MM. Do the math. ACRV is now my largest position. GLTALs!!

0 · Reply

Trinity031983 Nov. 14 at 1:38 PM

$ACRV https://tipranks.onelink.me/WJho/5ym5slw0

0 · Reply

Trinity031983 Nov. 14 at 1:12 PM

$ACRV https://tipranks.onelink.me/WJho/35lnqr16

0 · Reply

Trinity031983 Nov. 14 at 1:08 PM

$ACRV https://tipranks.onelink.me/WJho/gmlsldqi

0 · Reply

trading_momentum_x Nov. 14 at 12:22 PM

0 · Reply

d_risk Nov. 13 at 9:38 PM

1 · Reply

Monty3030 Nov. 13 at 9:21 PM

$ACRV Earnings Report.. Looking good!! https://www.stocktitan.net/news/ACRV/acrivon-therapeutics-reports-third-quarter-2025-financial-results-hqypngwadrf8.html

0 · Reply

MH2024 Nov. 13 at 3:08 PM

$ACRV I think we will see some near term ups and downs and the real movement after the new year.

0 · Reply

Jstidd Nov. 13 at 2:29 PM

$ACRV i think they release earnings this week 🤞🏼

0 · Reply

Stockwatcher9999 Nov. 13 at 12:41 PM

$ACRV

0 · Reply

History101 Nov. 12 at 10:16 PM

$ACRV 854 watching 11/12/2025

0 · Reply

History101 Nov. 12 at 10:06 PM

$ACRV Great day Longs!!

0 · Reply

blackpoint01 Nov. 12 at 9:01 PM

$ACRV we don’t want new people in here that aren’t going to hold until $10.

1 · Reply

squiggleburp Nov. 12 at 8:37 PM

$ACRV Super itchy trade.

1 · Reply

PLATINUM_TRADES Nov. 12 at 8:23 PM

$ACRV $2.30 Is the 200 let it break then has a shot at $2.50 imo👌👌

0 · Reply

Monty3030 Nov. 12 at 8:20 PM

$ACRV Time for some action, I see!!

0 · Reply

squiggleburp Nov. 12 at 7:14 PM

$ACRV Popped up my police 👮 scanner. Do we run? I will have a look IF I sober up????

0 · Reply

Dani_G_German Nov. 12 at 7:04 PM

$ACRV well if you needed confirmation that was it. See ya at the top

1 · Reply

PLATINUM_TRADES Nov. 12 at 7:01 PM

$ACRV Nice going I told u $2.00's soon 👍

0 · Reply

Momo7002momo Nov. 10 at 8:11 PM

$ACRV and $SCYX about to break out here

0 · Reply

Market Cap	65.11M
Revenue (ttm)	0.00
Net Income (ttm)	-80.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,186,600
Avg Vol	1,900,074
Day's Range	N/A - N/A
Shares Out	31.46M
Stochastic %K	81%
Beta	1.82
Analysts	Strong Sell
Price Target	$11.17